Menu Back to Event-Details

Panel Moderator

Track:
Hot Topic/Stand Alone

Day & Time:
April 17, 9:00AM - 10:30AM (Central Europe Standard Time)

Session Number:
SAT1

Type:
Session

Title:
Towards Access 2030: How Can Strengthening of Regulatory Systems Contribute?

Chair(s):
Petra Doerr, PharmD, PhD, RPh
Deputy Executive Director
Swissmedic, Switzerland

Description:
Various initiatives and programmes are underway to improve access to medicines in low- and middle-income countries. An important component of achieving this goal is to strengthen the regulatory systems of those countries. Many stakeholders (and many resources) are involved and engaged. However, do all these efforts show tangible results? Would better coordination improve the overall outcome? And what else need to be done to achieve the goals?

Presentation(s) & Speaker(s):
Panel Moderator
Murray M. Lumpkin, DIAFellow, MD, MSc
Deputy Director, Regulatory Affairs, Lead Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation, United States

Towards access 2030: An Overview of WHO Efforts in Regulatory Systems Strengthening
Emer Cooke, MBA
Head of Regulation of Medicines and other Health Technologies
World Health Organization (WHO) , Switzerland

What Can Regulators in LMIC Do to Better Utilize the Scarce Resources in Order to Improve the Access to Priority Medicines?
Delese Mimi Darko, MBA, RPh, RAC
Ag. Deputy Chief Executive; Safety Monitoring & Clinical Trials Division
Food and Drugs Authority, Ghana

Panel Discussion
Thomas B. Cueni, MBA
Director General
IFPMA, Switzerland

Panel Discussion
Petra Doerr, PharmD, PhD, RPh
Deputy Executive Director
Swissmedic, Switzerland

Panel Discussion
Guido Rasi, MD
Executive Director
European Medicines Agency (EMA), European Union, United Kingdom

Panel Discussion
Alex Schulze
Co-Head Division Global Programme Health
Swiss Agency For Development Cooperation, Switzerland

Panel Discussion
Hiiti Sillo
Director General
Tanzania Food & Drug Authority (TFDA), Tanzania, United Republic of

Panel Discussion
Nathalie Strub Wourgaft
Medical Director
Drugs For Neglected Diseases Initiative (dndi), Switzerland